Technology
Health
Biotechnology

ContraFect

$0.47
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.10 (27.78%) Today
+$0.01 (2.17%) After Hours

Why Robinhood?

You can buy or sell ContraFect and other stocks, options, ETFs, and crypto commission-free!

About

ContraFect Corp. engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. Read More The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Employees
23
Headquarters
Yonkers, New York
Founded
2008
Market Cap
28.59M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
348.32K
High Today
$0.47
Low Today
$0.3638
Open Price
$0.37
Volume
1.85M
52 Week High
$2.93
52 Week Low
$0.355

Collections

Technology
Health
Biotechnology
2014 IPO
US
North America

News

Markets InsiderMar 13

ContraFect to Present at the Oppenheimer 29th Annual Healthcare Conference

YONKERS, New York, March 13, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company's Chairman and Chief Executive Officer, will participate in the 29th Annual Oppenheimer Healthcare Conference on Wednesday, March 20, 2019, at 3:55 PM ET in New York City.

245
MarketBeatMar 6

Stock Price, News, & Analysis for ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States.

46
Guru FocusFeb 25

Glancy Prongay & Murray LLP Continues Investigation on Behalf of ContraFect Corporation Investors (CFRX)

LOS ANGELES, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of ContraFect Corporation ( CFRX) investors concerning the Company and its directors’ and officers’ possible violations of state laws. If you purchased ContraFect stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East, Su...

299

Earnings

-$0.27
-$0.19
-$0.10
-$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.10 per share
Actual
-$0.08 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.